Recent developments in drug therapy for multiple sclerosis (Q33639891)

28 July 2017

1 reference

title

Recent developments in drug therapy for multiple sclerosis (English)

1 reference

28 July 2017

P F Smith

1

1 reference

28 July 2017

C L Darlington

series ordinal

2

1 reference

28 July 2017

publication date

1 April 1999

1 reference

Multiple Sclerosis Journal

28 July 2017

published in

1 reference

28 July 2017

volume

5

1 reference

28 July 2017

issue

2

1 reference

28 July 2017

page(s)

110-120

1 reference

How should we proceed with disease-modifying treatments for multiple sclerosis?

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Multiple sclerosis therapy. A practical guide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Emerging Treatments in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Multiple sclerosis: immune mechanism and update on current therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Management of Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Lasting reduction of severe spasticity after ending chronic treatment with intrathecal baclofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Tizanidine. A review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

An antispasticity effect of threonine in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

The new generation of antiepileptic drugs: advantages and disadvantages

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

The Perceived Effects of Smoked Cannabis on Patients with Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Cannabinoid receptors and modulation of cyclic AMP accumulation in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

A pilot study of gabapentin as treatment for acquired nystagmus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Open label gabapentin treatment for pain in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Cause of death in patients attending multiple sclerosis clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Corticosteroids and optic neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: Increased interleukin-4 production and associated eosinophilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Effect of steroids on Gd-enhancing lesions before and during recombinant beta interferon 1a treatment in relapsing remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Overview of azathioprine treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Randomised double blind controlled trial of cyclosporin in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

The treatment of chronic progressive multiple sclerosis with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Treatment effects of monthly intravenous immunoglobulin on patients with relapsing - remitting Multiple Sclerosis: Further analyses of the Austrian immunoglobulin in MS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Intravenous immunoglobulin treatment in Multiple Sclerosis and experimental autoimmune encephalomyelitis - the Israeli Experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Intravenous immune globulin therapy for neurologic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Immunoglobulins reactive with myelin basic protein promote CNS remyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Inhibition of the Progression of Multiple Sclerosis by Linomide Is Associated with Upregulation of CD4 /CD45RA Cells and Downregulation of CD4 /CD45RO Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Beta-interferon and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Managing side effects of interferon-beta in patients with relapsing-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Characterization of MRI response to treatment with interferon beta-1b: Contrast-enhancing MRI lesion frequency as a primary outcome measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Immunoregulatory effects of interferon-beta and interacting cytokines on human vascular endothelial cells. Implications for multiple sclerosis autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Effects of β-IFN-1b treatment in MS patients on adhesion between PBMNCs, HUVECs and MS-HBECs: an in vivo and in vitro study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Side effect profile of interferon beta-1b in MS: results of an open label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

A review of the clinical efficacy profile of copolymer 1: new U.S. phase III trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-β mRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Growth factors and myelin regeneration in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Functional and neurophysiological evidence of the efficacy of trophic pharmacotherapy using an adrenocorticotrophic hormone4-9 analog in experimental allergic encephalomyelitis, an animal model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Longitudinal in vivo magnetic resonance imaging studies in experimental allergic encephalomyelitis: effect of a neurotrophic treatment on cortical lesion development

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

Oral versus intravenous corticosteroids in acute relapses of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177/135245859900500208

10.1177/135245859900500208

21 January 2018

Identifiers

DOI

1 reference

release_vgt2i7izazdeljm42xpjerfdl4

28 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vgt2i7izazdeljm42xpjerfdl4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference